Several authors have suggested that CAR T cell-induced CRS is mediated by IL-6, IL-1, and nitric oxide produced by recipient macrophages, and can be attenuated by nitric oxide inhibitors, IL-6 antagonists such as tocilizumab, and IL-1 blockade by Anakinra (37, 38). Here, IL1B is linked to congenital rubella syndrome.